The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions
Cardiovascular disease (CVD) is the major cause of death and disability globally1 and
affects approximately half of all individuals over their lifetimes. 2 The CVD burden has …
affects approximately half of all individuals over their lifetimes. 2 The CVD burden has …
[PDF][PDF] Evaluating causes of death and morbidity in Iran, global burden of diseases, injuries, and risk factors study 2010
BACKGROUND: we aimed to recap and highlight the major results of the Global Burden of
Diseases, Injuries, and Risk Factors Study 2010 by mortality and morbidity to clarify the …
Diseases, Injuries, and Risk Factors Study 2010 by mortality and morbidity to clarify the …
[PDF][PDF] Reducing the burden of chronic diseases: a neglected agenda in Iranian health care system, requiring a plan for action
SS GHAJARIEH, F Kamangar, H Poustchi… - 2010 - sid.ir
Chronic non-communicable diseases cause substantial morbidity and mortality in both
developed and develo** countries. Current studies indicate an increasing burden of …
developed and develo** countries. Current studies indicate an increasing burden of …
A pilot double‐blind randomised placebo‐controlled trial of the effects of fixed‐dose combination therapy ('polypill') on cardiovascular risk factors
Aim: Our objective was to investigate the effects and tolerability of fixed‐dose combination
therapy on blood pressure and LDL in adults without elevated blood pressure or lipid levels …
therapy on blood pressure and LDL in adults without elevated blood pressure or lipid levels …
Polypill therapy, subclinical atherosclerosis, and cardiovascular events—implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of …
Objectives: This study examines whether the coronary artery calcium (CAC) score can be
used to define the target population to treat with a polypill. Background: Prior studies have …
used to define the target population to treat with a polypill. Background: Prior studies have …
Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial
MR Ostovaneh, H Poustchi… - European journal of …, 2015 - journals.sagepub.com
Background The complexity of treatment regimens, costs and pill burden decrease the
medication adherence and contribute to shortfall in cardiovascular preventive drug …
medication adherence and contribute to shortfall in cardiovascular preventive drug …
[PDF][PDF] Prevalence, awareness, treatment, control, and correlates of hypertension in the pars cohort study
Background: High blood pressure is an important risk factor for all-cause mortality and
cardiovascular mortality and morbidity among Iranians. We aimed to estimate its prevalence …
cardiovascular mortality and morbidity among Iranians. We aimed to estimate its prevalence …
[HTML][HTML] Cardiovascular disease deaths and years of life lost attributable to non-optimal systolic blood pressure and hypertension in Northeastern Iran
SG Sepanlou, RB Newson, H Poustchi… - Archives of Iranian …, 2015 - ncbi.nlm.nih.gov
Background High blood pressure is the second most important risk factor of cardiovascular
diseases (CVDs) in Iran. It is imperative to estimate the burden of CVDs that can be averted …
diseases (CVDs) in Iran. It is imperative to estimate the burden of CVDs that can be averted …
The clinical performance of an office-based risk scoring system for fatal cardiovascular diseases in North-East of Iran
Background Cardiovascular diseases (CVD) are becoming major causes of death in
develo** countries. Risk scoring systems for CVD are needed to prioritize allocation of …
develo** countries. Risk scoring systems for CVD are needed to prioritize allocation of …
Polypill: the evidence and the promise
Theoretical models suggest that a polypill containing low-dose aspirin, three blood pressure-
lowering drugs at half dose and a potent statin, administered to a large proportion of the …
lowering drugs at half dose and a potent statin, administered to a large proportion of the …